Elsevier

Vaccine

Volume 26, Issue 44, 16 October 2008, Pages 5567-5574
Vaccine

Decline in influenza-associated mortality among Dutch elderly following the introduction of a nationwide vaccination program

https://doi.org/10.1016/j.vaccine.2008.08.003Get rights and content

Abstract

With a retrospective nationwide cohort study in the Netherlands over 1992–2003, using mortality and viral surveillance data, the aim was to assess by means of rate difference methods the influenza-associated mortality in the elderly before and after the introduction of a nationwide influenza vaccination program in 1996 (vaccination coverage raised from below 50 to 80%). The average annual influenza-associated mortality declined in the years before and after the introduction from 131 to 105 per 100,000 persons (relative risk 0.80). The decline was largest in the age group 65–69 years (relative risk 0.54) and less in those aged 75 years and older. Validation by Serfling-type regression analysis revealed similar results. In conclusion, routine influenza vaccination among Dutch elderly was associated with a significant decrease in influenza-associated mortality, notably in those aged 65–69 years.

Introduction

Influenza epidemics are held responsible for substantial morbidity and mortality, particularly among the elderly [1], [2], [3], [4], [5]. Several observational cohort studies reported influenza vaccination to confer substantial reductions in hospitalisations for acute respiratory, cardiovascular, and cerebrovascular events and all-cause mortality during influenza seasons [6], [7], [8], [9], [10], [11]. It has therefore been hypothesized that increasing influenza vaccination coverage rates should lead to a decrease in influenza-associated mortality. Surprisingly, data from ecological trend studies conducted in the United States and Italy did not support this hypothesis [12], [13], and the benefits of vaccination have been questioned more and more. Yet, these studies may have been hindered by the major disparities in vaccination rates by geography as well as by socioeconomic, demographic, and health characteristics making it very difficult to estimate individual benefit from population-level data [6], [14].

The Netherlands encompass a rather homogeneous population, and influenza vaccination approximated 80% after the introduction of routine influenza vaccination among all elderly in 1996. The aim of the current study was to assess the impact of influenza vaccination on influenza-attributable mortality by comparing influenza-attributable mortality among elderly before and after the introduction of the vaccination program.

Section snippets

Study population

Weekly all-cause mortality data of all Dutch citizens aged 65 years and older were obtained during the respiratory seasons 1992–2003 from Statistics Netherlands, Voorburg/Heerlen, the Netherlands. Each respiratory season started in week 27 of 1 year and lasted until week 26 of the next year.

The Dutch primary care Influenza vaccination program

Until the respiratory season 1996–1997, influenza vaccination was recommended only for persons with certain high-risk medical conditions in the Netherlands (such as chronic heart, lung and renal disease).

Results

In Fig. 3 the weekly mortality rate among persons aged 65 years and older is displayed and influenza virus- and RSV-active periods are indicated. Total winter excess mortality attributable to influenza increased about 10-fold from the age category 65–69 years to the category 80 years and older (Table 1, Table A1). Among all persons aged 65 years and older, influenza-associated mortality decreased over the period from 1992 to 2003 (Fig. 4; Table A2). In the seasons before the introduction of

Discussion

This nationally representative ecological study demonstrated a decline in influenza-associated mortality among elderly after the start of the large-scale influenza vaccination program in the Netherlands in 1996, notably in those aged 65–69 years.

Our methods bare some potential limitations. First of all, we based the estimates of deaths attributable to influenza on epidemiological data. These data naturally lack direct evidence for the cause of death. Additionally, we determined

Acknowledgements

Dr. Nichol reports having served as a consultant to the influenza vaccine manufacturers Sanofi Pasteur, MedImmune, GSK, and Novartis. Dr. Nichol has received or will receive grant support from Sanofi Pasteur and GSK. This study was funded by the Health Council of the Netherlands.

References (28)

  • K.L. Nichol et al.

    Effectiveness of influenza vaccine in the community-dwelling elderly

    N Engl J Med

    (2007)
  • K.L. Nichol et al.

    The health and economic benefits of influenza vaccination for healthy and at-risk persons aged 65–74 years old

    Pharacoeconomics

    (1999)
  • E. Hak et al.

    Influence of high-risk medical conditions on the effectiveness of influenza vaccination among elderly members of 3 large managed-care organizations

    Clin Infect Dis

    (2002)
  • K.L. Nichol et al.

    Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly

    N Eng J Med

    (2003)
  • Cited by (0)

    View full text